



Clinical trial results:

A pragmatic pilot randomised phase II controlled trial of Prothrombin Complex Concentrates (PCC) versus Fresh Frozen Plasma (FFP) in adult patients who are Undergoing Heart Surgery (PROPHECY)

Summary

| | |
|--------------------------|-----------------|
| EudraCT number | 2018-003041-41 |
| Trial protocol | GB |
| Global end of trial date | 29 January 2020 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 11 November 2020 |
| First version publication date | 11 November 2020 |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 012507 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03715348 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Queen Mary University of London |
| Sponsor organisation address | 5 Walden Street, London, United Kingdom, E1 2EF |
| Public contact | Dr Mays Jawad, Queen Mary University of London, +44 020 7882 7252, research.governance@qmul.ac.uk |
| Scientific contact | Dr Laura Green, Barts Health NHS Trust and NHSBT, +44 0208 957 2756, laura.green27@nhs.net |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 29 January 2020 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 29 January 2020 |
| Global end of trial reached? | Yes |
| Global end of trial date | 29 January 2020 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To determine the recruitment rate – defined as the proportion of participants who consent to the randomised study out of all eligible patients, and the proportion who are randomised and receive intervention out of consenting participants .

Protection of trial subjects:

Patients who were not randomised to study intervention were treated as per standard care. Patients who were randomised to receive study intervention were treated as per standard care following one dose of the intervention they were randomised to. Patients were free to withdraw from the study at any time without giving reasons and without prejudicing his/her further treatment. Safety events were regularly reviewed by an independent Data Monitoring Committee, who advised the investigators if there were any safety concerns.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 28 February 2019 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|---------------------|
| Country: Number of subjects enrolled | United Kingdom: 134 |
| Worldwide total number of subjects | 134 |
| EEA total number of subjects | 134 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 53 |
| From 65 to 84 years | 77 |

| | |
|-------------------|---|
| 85 years and over | 4 |
|-------------------|---|

Subject disposition

Recruitment

Recruitment details:

Recruitment began on 28/02/2019 and ended on 28/10/2019.

Pre-assignment

Screening details: -

Pre-assignment period milestones

| | |
|------------------------------|-----|
| Number of subjects started | 134 |
| Number of subjects completed | 134 |

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|--|---------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Fresh Frozen Plasma (FFP) |
| Arm description: - | |
| Arm type | Active comparator |
| Investigational medicinal product name | Fresh Frozen Plasma (FFP) |
| Investigational medicinal product code | |
| Other name | FFP |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

A 15mL/Kg dose of FFP was used which was rounded up to the following:

- 3 units if ≤ 60 kg
- 4 units if 61 to 90 kg
- 5 units if > 90 kg

FFP must be administered by intravenous infusion after thawing, using an infusion set, over 5-20 min per unit. There is no maximum allowed dose for FFP. If bleeding continues, after administration of the first dose of FFP, patient will continue to receive standard care, and this may require further FFP transfusion.

FFP will be stored at $\leq -25^{\circ}\text{C}$ for up to 36 months. Prior to use, FFP requires thawing at 37°C (between 33°C - 37°C is acceptable) for 20 minutes in a waterbath or other equipment designed for the purpose, within a vacuum-sealed overwrap bag according to a validated procedure. Once thawed, FFP must not be refrozen and should be transfused as soon as possible. Transfusion of FFP should be completed within 4 hours of issue out of a controlled temperature environment. Administration of FFP should be by ABO-blood group compatibility.

| | |
|--|--|
| Arm title | Prothrombin Complex Concentrate (PCC) |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | Prothrombin Complex Concentrate (PCC) |
| Investigational medicinal product code | |
| Other name | PCC, Octaplex |
| Pharmaceutical forms | Powder and solvent for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Octaplex is presented as a powder and comes in two different package sizes: 500 IU and 1000 IU. The

following dose schedule was used:

<=60 kg 500 IU (1 vial)

61 – 90 kg 1000 IU (2 vials)

>90 kg 1,500 IU (3 vials)

Octaplex will be administered intravenously at a slow speed: Initially 1 mL per minute, not faster than 2-3 mL per minute will be administered. If bleeding continues after administration of the first dose of PCC, patient will continue to receive standard care, and this does not include PCC. Therefore, no further PCC will be administered to patient.

Octaplex should be stored below 25°C for up to 3 years, and in its original package in order to protect from light. After reconstitution the solution must be used immediately. Please refer to SmPC for instructions for reconstitution and infusion.

| | |
|--|-----------------|
| Arm title | Not randomised |
| Arm description: | |
| Patient did not bleed during or within 24 hours of surgery and was not randomised to receive either FFP or PCC | |
| Arm type | No intervention |
| No investigational medicinal product assigned in this arm | |

| Number of subjects in period 1 | Fresh Frozen Plasma (FFP) | Prothrombin Complex Concentrate (PCC) | Not randomised |
|---------------------------------------|---------------------------|---------------------------------------|----------------|
| | | | |
| Started | 25 | 25 | 84 |
| Completed | 25 | 25 | 84 |

Baseline characteristics

Reporting groups

| | |
|--|---------------------------------------|
| Reporting group title | Fresh Frozen Plasma (FFP) |
| Reporting group description: - | |
| Reporting group title | Prothrombin Complex Concentrate (PCC) |
| Reporting group description: - | |
| Reporting group title | Not randomised |
| Reporting group description: | |
| Patient did not bleed during or within 24 hours of surgery and was not randomised to receive either FFP or PCC | |

| Reporting group values | Fresh Frozen Plasma (FFP) | Prothrombin Complex Concentrate (PCC) | Not randomised |
|---|---------------------------|---------------------------------------|----------------|
| Number of subjects | 25 | 25 | 84 |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Age continuous Units: years | | | |
| median | 66 | 69 | 67.5 |
| inter-quartile range (Q1-Q3) | 57 to 74 | 63 to 73 | 57 to 75.5 |
| Gender categorical Units: Subjects | | | |
| Female | 9 | 9 | 31 |
| Male | 16 | 16 | 53 |
| Race Units: Subjects | | | |
| White | 20 | 21 | 66 |
| Asian | 1 | 1 | 6 |
| African | 1 | 0 | 4 |
| Mixed | 0 | 0 | 1 |
| Unknown/Not reported | 3 | 3 | 7 |
| Diabetes mellitus Units: Subjects | | | |
| Non-diabetic | 19 | 19 | 66 |
| Diabetic | 6 | 6 | 13 |
| Unknown | 0 | 0 | 5 |
| Hypertension Units: Subjects | | | |

| | | | |
|-----------------------------|--------|--------|--------|
| non-Hypertensive | 12 | 6 | 29 |
| Hypertensive | 13 | 19 | 50 |
| Unknown | 0 | 0 | 5 |
| Angina | | | |
| History of angina | | | |
| Units: Subjects | | | |
| No | 19 | 19 | 67 |
| Yes | 6 | 6 | 12 |
| Unknown | 0 | 0 | 5 |
| Previous PCI | | | |
| Units: Subjects | | | |
| No | 23 | 22 | 77 |
| Yes | 2 | 3 | 2 |
| Unknown | 0 | 0 | 5 |
| Previous cardiac Surgery | | | |
| Units: Subjects | | | |
| No | 24 | 23 | 75 |
| Yes | 1 | 2 | 4 |
| Unknown | 0 | 0 | 5 |
| Type of surgery | | | |
| Units: Subjects | | | |
| Elective surgery | 20 | 19 | 71 |
| Non-elective Surgery | 5 | 6 | 8 |
| Unknown | 0 | 0 | 5 |
| Procedure | | | |
| Units: Subjects | | | |
| Valve only | 7 | 5 | 34 |
| Major aortic only | 0 | 2 | 3 |
| CABG + valve | 5 | 6 | 17 |
| complex/combined procedures | 13 | 12 | 25 |
| Unknown | 0 | 0 | 5 |
| Antiplatelet use | | | |
| Units: Subjects | | | |
| No | 18 | 18 | 78 |
| Yes | 7 | 7 | 1 |
| Unknown | 0 | 0 | 5 |
| Anticoagulant use | | | |
| Units: Subjects | | | |
| No | 18 | 16 | 72 |
| Yes | 7 | 9 | 7 |
| Unknown | 0 | 0 | 5 |
| Weight | | | |
| Units: kg | | | |
| arithmetic mean | 80.5 | 76.1 | 78 |
| standard deviation | ± 16.2 | ± 19.7 | ± 17.3 |
| Height | | | |
| Units: cm | | | |
| arithmetic mean | 168.1 | 167.3 | 169.3 |
| standard deviation | ± 10.7 | ± 9.5 | ± 10.2 |
| BMI | | | |
| Units: kg/m2 | | | |

| | | | |
|---|----------------------|----------------------|----------------------|
| arithmetic mean standard deviation | 28.5 ± 5.3 | 27.0 ± 5.8 | 27.1 ± 5.8 |
| EuroSCORE Units: unit median inter-quartile range (Q1-Q3) | 2.94 1.83 to 4.86 | 3.73 2.25 to 5.86 | 2.19 1.26 to 3.94 |
| EQ5D index score Units: unit median inter-quartile range (Q1-Q3) | 0.9 0.75 to 0.96 | 0.9 0.78 to 1 | 0.86 0.7 to 0.94 |
| Hemoglobin | | | |
| laboratory test at screening | | | |
| Units: g/L median inter-quartile range (Q1-Q3) | 135 121 to 145 | 130 124 to 141 | 133 130 to 135 |
| Platelet count | | | |
| laboratory test at screening | | | |
| Units: Thousand/uL median inter-quartile range (Q1-Q3) | 227 184 to 271 | 239 194 to 259 | 227 184 to 271 |
| PT | | | |
| Prothrombin time at screening | | | |
| Units: seconds median inter-quartile range (Q1-Q3) | 11 11 to 12 | 11 11 to 12 | 11 10.8 to 11.8 |
| APTT | | | |
| Activated partial thromboplastin time at screening | | | |
| Units: seconds median inter-quartile range (Q1-Q3) | 25 23 to 27 | 27 25 to 29 | 26 24 to 28 |

| | | | |
|--|-------|--|--|
| Reporting group values | Total | | |
| Number of subjects | 134 | | |
| Age categorical Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |
| Adults (18-64 years) | 0 | | |
| From 65-84 years | 0 | | |
| 85 years and over | 0 | | |
| Age continuous Units: years median inter-quartile range (Q1-Q3) | - | | |

| | | | |
|-----------------------------|-----|--|--|
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 49 | | |
| Male | 85 | | |
| Race | | | |
| Units: Subjects | | | |
| White | 107 | | |
| Asian | 8 | | |
| African | 5 | | |
| Mixed | 1 | | |
| Unknown/Not reported | 13 | | |
| Diabetes mellitus | | | |
| Units: Subjects | | | |
| Non-diabetic | 104 | | |
| Diabetic | 25 | | |
| Unknown | 5 | | |
| Hypertension | | | |
| Units: Subjects | | | |
| non-Hypertensive | 47 | | |
| Hypertensive | 82 | | |
| Unknown | 5 | | |
| Angina | | | |
| History of angina | | | |
| Units: Subjects | | | |
| No | 105 | | |
| Yes | 24 | | |
| Unknown | 5 | | |
| Previous PCI | | | |
| Units: Subjects | | | |
| No | 122 | | |
| Yes | 7 | | |
| Unknown | 5 | | |
| Previous cardiac Surgery | | | |
| Units: Subjects | | | |
| No | 122 | | |
| Yes | 7 | | |
| Unknown | 5 | | |
| Type of surgery | | | |
| Units: Subjects | | | |
| Elective surgery | 110 | | |
| Non-elective Surgery | 19 | | |
| Unknown | 5 | | |
| Procedure | | | |
| Units: Subjects | | | |
| Valve only | 46 | | |
| Major aortic only | 5 | | |
| CABG + valve | 28 | | |
| complex/combined procedures | 50 | | |
| Unknown | 5 | | |
| Antiplatelet use | | | |
| Units: Subjects | | | |

| | | | |
|--|-----|--|--|
| No | 114 | | |
| Yes | 15 | | |
| Unknown | 5 | | |
| Anticoagulant use | | | |
| Units: Subjects | | | |
| No | 106 | | |
| Yes | 23 | | |
| Unknown | 5 | | |
| Weight | | | |
| Units: kg | | | |
| arithmetic mean | | | |
| standard deviation | - | | |
| Height | | | |
| Units: cm | | | |
| arithmetic mean | | | |
| standard deviation | - | | |
| BMI | | | |
| Units: kg/m2 | | | |
| arithmetic mean | | | |
| standard deviation | - | | |
| EuroSCORE | | | |
| Units: unit | | | |
| median | | | |
| inter-quartile range (Q1-Q3) | - | | |
| EQ5D index score | | | |
| Units: unit | | | |
| median | | | |
| inter-quartile range (Q1-Q3) | - | | |
| Hemoglobin | | | |
| laboratory test at screening | | | |
| Units: g/L | | | |
| median | | | |
| inter-quartile range (Q1-Q3) | - | | |
| Platelet count | | | |
| laboratory test at screening | | | |
| Units: Thousand/uL | | | |
| median | | | |
| inter-quartile range (Q1-Q3) | - | | |
| PT | | | |
| Prothrombin time at screening | | | |
| Units: seconds | | | |
| median | | | |
| inter-quartile range (Q1-Q3) | - | | |
| APTT | | | |
| Activated partial thromboplastin time at screening | | | |
| Units: seconds | | | |
| median | | | |
| inter-quartile range (Q1-Q3) | - | | |

Subject analysis sets

| | |
|--|-------------------------|
| Subject analysis set title | Per protocol |
| Subject analysis set type | Per protocol |
| Subject analysis set description: includes only those patients who completed the treatment originally allocated | |
| Subject analysis set title | Intention-to-treat |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: includes all patients as originally allocated after randomisation | |
| Subject analysis set title | Safety population |
| Subject analysis set type | Safety analysis |
| Subject analysis set description: Includes all patients who received FFP or PCC, in order to obtain data on event rates in both groups to help estimate the sample size for the large trial | |
| Subject analysis set title | Eligible patients |
| Subject analysis set type | Full analysis |
| Subject analysis set description: Patients who met the eligibility criteria for the trial. The number in the analysis set is 180 with 134 of these consenting. | |
| Subject analysis set title | Consenting patients |
| Subject analysis set type | Full analysis |
| Subject analysis set description: All eligible patients who consent | |
| Subject analysis set title | Non-consenting patients |
| Subject analysis set type | Full analysis |
| Subject analysis set description: Proportion of eligible patients who do not consent to enter trial | |
| Subject analysis set title | FFP per protocol |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Fresh Frozen Plasma (FFP) per protocol analysis set | |
| Subject analysis set title | PCC per protocol |
| Subject analysis set type | Per protocol |
| Subject analysis set description: PCC per protocol analysis set | |

| Reporting group values | Per protocol | Intention-to-treat | Safety population |
|---|--------------|--------------------|-------------------|
| Number of subjects | 42 | 50 | 55 |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |

| | | | |
|--|----------------|----------------|----------------|
| Age continuous Units: years median inter-quartile range (Q1-Q3) | 68 57 to 73 | 68 60 to 74 | 68 56 to 74 |
| Gender categorical Units: Subjects | | | |
| Female | 16 | 18 | 19 |
| Male | 26 | 32 | 36 |
| Race Units: Subjects | | | |
| White | 34 | 41 | 45 |
| Asian | 2 | 2 | 2 |
| African | 1 | 1 | 1 |
| Mixed | 0 | 0 | 0 |
| Unknown/Not reported | 5 | 6 | 7 |
| Diabetes mellitus Units: Subjects | | | |
| Non-diabetic | 33 | 38 | 44 |
| Diabetic | 9 | 12 | 11 |
| Unknown | 0 | 0 | 0 |
| Hypertension Units: Subjects | | | |
| non-Hypertensive | 16 | 18 | 19 |
| Hypertensive | 26 | 32 | 36 |
| Unknown | 0 | 0 | 0 |
| Angina | | | |
| History of angina Units: Subjects | | | |
| No | 32 | 38 | 42 |
| Yes | 10 | 12 | 13 |
| Unknown | 0 | 0 | 0 |
| Previous PCI Units: Subjects | | | |
| No | 38 | 45 | 50 |
| Yes | 4 | 5 | 5 |
| Unknown | 0 | 0 | 0 |
| Previous cardiac Surgery Units: Subjects | | | |
| No | 39 | 47 | 51 |
| Yes | 3 | 3 | 4 |
| Unknown | 0 | 0 | 0 |
| Type of surgery Units: Subjects | | | |
| Elective surgery | 31 | 39 | 43 |
| Non-elective Surgery | 11 | 11 | 12 |
| Unknown | 0 | 0 | 0 |
| Procedure Units: Subjects | | | |
| Valve only | 9 | 12 | 12 |
| Major aortic only | 2 | 2 | 3 |
| CABG + valve | 10 | 11 | 11 |

| | | | |
|--|--------------|--------------|----------------|
| complex/combined procedures | 21 | 25 | 29 |
| Unknown | 0 | 0 | 0 |
| Antiplatelet use | | | |
| Units: Subjects | | | |
| No | 30 | 36 | 42 |
| Yes | 12 | 14 | 13 |
| Unknown | 0 | 0 | 0 |
| Anticoagulant use | | | |
| Units: Subjects | | | |
| No | 38 | 34 | 38 |
| Yes | 14 | 16 | 17 |
| Unknown | 0 | 0 | 0 |
| Weight | | | |
| Units: kg | | | |
| arithmetic mean | 78.0 | 78.3 | 77.3 |
| standard deviation | ± 17.7 | ± 18.0 | ± 17.6 |
| Height | | | |
| Units: cm | | | |
| arithmetic mean | 167.6 | 167.7 | 168.5 |
| standard deviation | ± 10.0 | ± 10.1 | ± 10.3 |
| BMI | | | |
| Units: kg/m2 | | | |
| arithmetic mean | 27.7 | 27.8 | 27.1 |
| standard deviation | ± 5.3 | ± 5.6 | ± 5.4 |
| EuroSCORE | | | |
| Units: unit | | | |
| median | 3.51 | 3.42 | 3.47 |
| inter-quartile range (Q1-Q3) | 1.94 to 5.46 | 1.83 to 5.46 | 1.83 to 5.86 |
| EQ5D index score | | | |
| Units: unit | | | |
| median | 0.87 | 0.90 | 0.87 |
| inter-quartile range (Q1-Q3) | 0.75 to 0.95 | 0.76 to 1 | 0.75 to 0.95 |
| Hemoglobin | | | |
| laboratory test at screening | | | |
| Units: g/L | | | |
| median | 133 | 133 | 132 |
| inter-quartile range (Q1-Q3) | 123 to 142 | 123 to 145 | 122 to 142.5 |
| Platelet count | | | |
| laboratory test at screening | | | |
| Units: Thousand/uL | | | |
| median | 241 | 238 | 227 |
| inter-quartile range (Q1-Q3) | 194 to 283 | 187 to 271 | 175.5 to 264.5 |
| PT | | | |
| Prothrombin time at screening | | | |
| Units: seconds | | | |
| median | 11.25 | 11.35 | 11.2 |
| inter-quartile range (Q1-Q3) | 10.8 to 11.9 | 10.8 to 12 | 10.8 to 11.9 |
| APTT | | | |
| Activated partial thromboplastin time at screening | | | |
| Units: seconds | | | |
| median | 26 | 26 | 26 |

| | | | |
|------------------------------|----------|----------|----------|
| inter-quartile range (Q1-Q3) | 24 to 28 | 24 to 28 | 24 to 28 |
|------------------------------|----------|----------|----------|

| Reporting group values | Eligible patients | Consenting patients | Non-consenting patients |
|---|---------------------------|---------------------------|-------------------------|
| Number of subjects | 134 | 134 | 46 |
| Age categorical Units: Subjects | | | |
| In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over | | | |
| Age continuous Units: years median inter-quartile range (Q1-Q3) | | 68 57 to 74 | |
| Gender categorical Units: Subjects | | | |
| Female Male | | 49 85 | |
| Race Units: Subjects | | | |
| White Asian African Mixed Unknown/Not reported | 107 85 5 1 59 | 107 85 5 1 13 | 46 |
| Diabetes mellitus Units: Subjects | | | |
| Non-diabetic Diabetic Unknown | 104 25 51 | 104 25 5 | 46 |
| Hypertension Units: Subjects | | | |
| non-Hypertensive Hypertensive Unknown | 47 82 51 | 47 82 5 | 46 |
| Angina | | | |
| History of angina Units: Subjects | | | |
| No Yes Unknown | 105 24 51 | 105 24 5 | 46 |
| Previous PCI | | | |

| | | | |
|------------------------------|-----|--------------|----|
| Units: Subjects | | | |
| No | 122 | 122 | |
| Yes | 7 | 7 | |
| Unknown | 51 | 5 | 46 |
| Previous cardiac Surgery | | | |
| Units: Subjects | | | |
| No | 122 | 122 | |
| Yes | 7 | 7 | |
| Unknown | 51 | 5 | 46 |
| Type of surgery | | | |
| Units: Subjects | | | |
| Elective surgery | 110 | 110 | |
| Non-elective Surgery | 19 | 19 | |
| Unknown | 51 | 5 | 46 |
| Procedure | | | |
| Units: Subjects | | | |
| Valve only | 46 | 46 | |
| Major aortic only | 5 | 5 | |
| CABG + valve | 28 | 28 | |
| complex/combined procedures | 50 | 50 | |
| Unknown | 51 | 5 | 46 |
| Antiplatelet use | | | |
| Units: Subjects | | | |
| No | 114 | 114 | |
| Yes | 15 | 15 | |
| Unknown | 51 | 5 | 46 |
| Anticoagulant use | | | |
| Units: Subjects | | | |
| No | 106 | 106 | |
| Yes | 23 | 23 | |
| Unknown | 51 | 5 | 46 |
| Weight | | | |
| Units: kg | | | |
| arithmetic mean | | 78.1 | |
| standard deviation | ± | ± 17.5 | ± |
| Height | | | |
| Units: cm | | | |
| arithmetic mean | | 168.7 | |
| standard deviation | ± | ± 10.1 | ± |
| BMI | | | |
| Units: kg/m2 | | | |
| arithmetic mean | | 27.4 | |
| standard deviation | ± | ± 5.4 | ± |
| EuroSCORE | | | |
| Units: unit | | | |
| median | | 2.50 | |
| inter-quartile range (Q1-Q3) | | 1.54 to 4.40 | |
| EQ5D index score | | | |
| Units: unit | | | |
| median | | 0.87 | |
| inter-quartile range (Q1-Q3) | | 0.70 to 0.95 | |

| | | | |
|--|--|--------------|--|
| Hemoglobin | | | |
| laboratory test at screening | | | |
| Units: g/L | | | |
| median | | 133 | |
| inter-quartile range (Q1-Q3) | | 123 to 144 | |
| Platelet count | | | |
| laboratory test at screening | | | |
| Units: Thousand/uL | | | |
| median | | 229 | |
| inter-quartile range (Q1-Q3) | | 185 to 271 | |
| PT | | | |
| Prothrombin time at screening | | | |
| Units: seconds | | | |
| median | | 11.1 | |
| inter-quartile range (Q1-Q3) | | 10.8 to 11.9 | |
| APTT | | | |
| Activated partial thromboplastin time at screening | | | |
| Units: seconds | | | |
| median | | 26 | |
| inter-quartile range (Q1-Q3) | | 24 to 28 | |

| Reporting group values | FFP per protocol | PCC per protocol | |
|--|------------------|------------------|--|
| Number of subjects | 21 | 21 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | | | |
| Preterm newborn infants (gestational age < 37 wks) | | | |
| Newborns (0-27 days) | | | |
| Infants and toddlers (28 days-23 months) | | | |
| Children (2-11 years) | | | |
| Adolescents (12-17 years) | | | |
| Adults (18-64 years) | | | |
| From 65-84 years | | | |
| 85 years and over | | | |
| Age continuous | | | |
| Units: years | | | |
| median | 63 | 69 | |
| inter-quartile range (Q1-Q3) | 54 to 73 | 63 to 73 | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 8 | 8 | |
| Male | 13 | 13 | |
| Race | | | |
| Units: Subjects | | | |
| White | 16 | 18 | |
| Asian | 1 | 1 | |
| African | 1 | 0 | |
| Mixed | 0 | 0 | |
| Unknown/Not reported | 3 | 2 | |
| Diabetes mellitus | | | |

| | | | |
|-----------------------------|--------|--------|--|
| Units: Subjects | | | |
| Non-diabetic | 17 | 16 | |
| Diabetic | 4 | 5 | |
| Unknown | 0 | 0 | |
| Hypertension | | | |
| Units: Subjects | | | |
| non-Hypertensive | 10 | 6 | |
| Hypertensive | 11 | 15 | |
| Unknown | 0 | 0 | |
| Angina | | | |
| History of angina | | | |
| Units: Subjects | | | |
| No | 16 | 16 | |
| Yes | 5 | 5 | |
| Unknown | 0 | 0 | |
| Previous PCI | | | |
| Units: Subjects | | | |
| No | 19 | 19 | |
| Yes | 2 | 2 | |
| Unknown | 0 | 0 | |
| Previous cardiac Surgery | | | |
| Units: Subjects | | | |
| No | 20 | 19 | |
| Yes | 1 | 2 | |
| Unknown | 0 | 0 | |
| Type of surgery | | | |
| Units: Subjects | | | |
| Elective surgery | 16 | 15 | |
| Non-elective Surgery | 5 | 6 | |
| Unknown | 0 | 0 | |
| Procedure | | | |
| Units: Subjects | | | |
| Valve only | 4 | 5 | |
| Major aortic only | 0 | 2 | |
| CABG + valve | 5 | 5 | |
| complex/combined procedures | 12 | 9 | |
| Unknown | 0 | 0 | |
| Antiplatelet use | | | |
| Units: Subjects | | | |
| No | 15 | 15 | |
| Yes | 6 | 6 | |
| Unknown | 0 | 0 | |
| Anticoagulant use | | | |
| Units: Subjects | | | |
| No | 15 | 13 | |
| Yes | 6 | 8 | |
| Unknown | 0 | 0 | |
| Weight | | | |
| Units: kg | | | |
| arithmetic mean | 79.8 | 76.2 | |
| standard deviation | ± 16.8 | ± 18.7 | |

| | | | |
|--|--------------|--------------|--|
| Height | | | |
| Units: cm | | | |
| arithmetic mean | 168.6 | 166.6 | |
| standard deviation | ± 11.0 | ± 9.1 | |
| BMI | | | |
| Units: kg/m2 | | | |
| arithmetic mean | 28.0 | 27.3 | |
| standard deviation | ± 5.3 | ± 5.4 | |
| EuroSCORE | | | |
| Units: unit | | | |
| median | 3.3 | 3.73 | |
| inter-quartile range (Q1-Q3) | 1.94 to 5.46 | 2.25 to 5.28 | |
| EQ5D index score | | | |
| Units: unit | | | |
| median | 0.90 | 0.87 | |
| inter-quartile range (Q1-Q3) | 0.72 to 0.98 | 0.78 to 0.94 | |
| Hemoglobin | | | |
| laboratory test at screening | | | |
| Units: g/L | | | |
| median | 135 | 130 | |
| inter-quartile range (Q1-Q3) | 123 to 145 | 124 to 140 | |
| Platelet count | | | |
| laboratory test at screening | | | |
| Units: Thousand/uL | | | |
| median | 261 | 240.5 | |
| inter-quartile range (Q1-Q3) | 172 to 300 | 201 to 258.5 | |
| PT | | | |
| Prothrombin time at screening | | | |
| Units: seconds | | | |
| median | 10.8 | 11.4 | |
| inter-quartile range (Q1-Q3) | 10.7 to 12.4 | 10.9 to 11.9 | |
| APTT | | | |
| Activated partial thromboplastin time at screening | | | |
| Units: seconds | | | |
| median | 25 | 26 | |
| inter-quartile range (Q1-Q3) | 23 to 27 | 25 to 28 | |

End points

End points reporting groups

| | |
|--|--|
| Reporting group title | Fresh Frozen Plasma (FFP) |
| Reporting group description: - | |
| Reporting group title | Prothrombin Complex Concentrate (PCC) |
| Reporting group description: - | |
| Reporting group title | Not randomised |
| Reporting group description: Patient did not bleed during or within 24 hours of surgery and was not randomised to receive either FFP or PCC | |
| Subject analysis set title | Per protocol |
| Subject analysis set type | Per protocol |
| Subject analysis set description: includes only those patients who completed the treatment originally allocated | |
| Subject analysis set title | Intention-to-treat |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: includes all patients as originally allocated after randomisation | |
| Subject analysis set title | Safety population |
| Subject analysis set type | Safety analysis |
| Subject analysis set description: Includes all patients who received FFP or PCC, in order to obtain data on event rates in both groups to help estimate the sample size for the large trial | |
| Subject analysis set title | Eligible patients |
| Subject analysis set type | Full analysis |
| Subject analysis set description: Patients who met the eligibility criteria for the trial. The number in the analysis set is 180 with 134 of these consenting. | |
| Subject analysis set title | Consenting patients |
| Subject analysis set type | Full analysis |
| Subject analysis set description: All eligible patients who consent | |
| Subject analysis set title | Non-consenting patients |
| Subject analysis set type | Full analysis |
| Subject analysis set description: Proportion of eligible patients who do not consent to enter trial | |
| Subject analysis set title | FFP per protocol |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Fresh Frozen Plasma (FFP) per protocol analysis set | |
| Subject analysis set title | PCC per protocol |
| Subject analysis set type | Per protocol |
| Subject analysis set description: PCC per protocol analysis set | |
| Primary: Proportion of eligible participants who consent | |
| End point title | Proportion of eligible participants who consent ^[1] |
| End point description: | |
| | |
| End point type | Primary |

End point timeframe:

8 months

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This is a single point estimate not a comparison between groups. The software does not allow entry of the confidence interval when there is only one group. The proportion (95% CI) for this endpoint is 0.744 (0.674, 0.806)

| End point values | Eligible patients | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 180 | | | |
| Units: subjects | | | | |
| Non-consenting | 46 | | | |
| Consenting | 134 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Proportion of participants who are randomised and receive intervention within 24 hours of surgery, out of all consenting participants

| | |
|-----------------|--|
| End point title | Proportion of participants who are randomised and receive intervention within 24 hours of surgery, out of all consenting participants ^[2] |
|-----------------|--|

End point description:

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

within 24 hours following surgery

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This is a single point estimate not a comparison between groups. The software does not allow entry of the confidence interval when there is only one group. The proportion (95% CI) for this endpoint is 0.351 (0.270, 0.438)

| End point values | Consenting patients | | | |
|---|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 134 | | | |
| Units: subjects | | | | |
| Not randomised and receiving intervention | 87 | | | |
| Randomised and receiving intervention | 47 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Time to administration of study drug (PCC) or control (FFP) to patient

| | |
|-----------------|--|
| End point title | Time to administration of study drug (PCC) or control (FFP) to patient |
|-----------------|--|

End point description:

Defined as time in minutes from telephoning laboratory to first administration to patient

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

within 24 hours following surgery

| End point values | Fresh Frozen Plasma (FFP) | Prothrombin Complex Concentrate (PCC) | Not randomised | |
|---------------------------------------|---------------------------|---------------------------------------|------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 22 ^[3] | 25 | 0 ^[4] | |
| Units: minutes | | | | |
| median (inter-quartile range (Q1-Q3)) | 72 (40 to 114) | 63 (36 to 108) | (to) | |

Notes:

[3] - 3 patients in the FFP group did not receive intervention

[4] - These patients consented but did not bleed and so did not enter the randomised part of the study.

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of patients for whom clinical outcome data were collected up to 90 days, or death, whichever occur first

| | |
|-----------------|---|
| End point title | Proportion of patients for whom clinical outcome data were collected up to 90 days, or death, whichever occur first |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

90 days following surgery

| End point values | Intention-to-treat | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 50 | | | |
| Units: subjects | | | | |
| Lost to follow-up | 4 | | | |
| 90 day Follow-up | 46 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of patients who bleed and are randomised within 24 hours of surgery

| | |
|-----------------|--|
| End point title | Proportion of patients who bleed and are randomised within 24 hours of surgery |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

within 24 hours following surgery

| End point values | Consenting patients | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 134 | | | |
| Units: subjects | | | | |
| Not randomised | 84 | | | |
| Randomised | 50 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of consenting patients who are not randomised within 24 hours of surgery

| | |
|-----------------|---|
| End point title | Proportion of consenting patients who are not randomised within 24 hours of surgery |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

within 24 hours following surgery

| End point values | Consenting patients | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 134 | | | |
| Units: subjects | | | | |
| Not randomised | 84 | | | |
| Randomised | 50 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of consenting participants who bleed and receive a protocol intervention within 24 hours of surgery (whether or not they are randomised)

| | |
|-----------------|---|
| End point title | Proportion of consenting participants who bleed and receive a protocol intervention within 24 hours of surgery (whether or not they are randomised) |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

within 24 hours following surgery

| End point values | Safety population | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 134 | | | |
| Units: subjects | | | | |
| No intervention | 79 | | | |
| Received study intervention | 55 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of patients for whom timing of administration, and completion of intervention(s) were documented

| | |
|-----------------|---|
| End point title | Proportion of patients for whom timing of administration, and completion of intervention(s) were documented |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

within 24 hours following surgery

| End point values | Intention-to-treat | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 50 | | | |
| Units: subjects | | | | |
| Data incomplete | 3 | | | |
| Data complete | 47 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of patients where there was protocol adherence

| | |
|-----------------|---|
| End point title | Proportion of patients where there was protocol adherence |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

90 days

| End point values | Intention-to-treat | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 50 | | | |
| Units: subjects | | | | |
| Protocol deviation | 8 | | | |
| Protocol adherence | 42 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Reasons for non-participation of eligible patients

| | |
|-----------------|--|
| End point title | Reasons for non-participation of eligible patients |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Recruitment period

| End point values | Eligible patients | | | |
|---|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 180 | | | |
| Units: 1.1 | | | | |
| Patient declined | 37 | | | |
| Language barrier | 6 | | | |
| Partial sightedness | 1 | | | |
| Procedure did not meet eligibility criteria | 1 | | | |
| Clinician decision | 1 | | | |
| Patient enrolled | 134 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Reasons for intervention non-compliance

| | |
|---|---|
| End point title | Reasons for intervention non-compliance |
| End point description: | |
| End point type | Secondary |
| End point timeframe: within 24 hours following surgery | |

| End point values | Per protocol | | | |
|--|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 50 | | | |
| Units: subjects | | | | |
| Stopped bleeding before intervention | 3 | | | |
| Already received FFP | 1 | | | |
| Received treatment to which they were randomised | 46 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of patients who do not consent to intervention, but agree to consenting of their de- identified data for up to 24 hours after surgery

| | |
|------------------------|--|
| End point title | Proportion of patients who do not consent to intervention, but agree to consenting of their de- identified data for up to 24 hours after surgery |
| End point description: | |
| End point type | Secondary |

End point timeframe:

Recruitment period

| End point values | Non-consenting patients | | | |
|-----------------------------|-------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 46 | | | |
| Units: subjects | | | | |
| Not available | 46 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change in PT from baseline to 1 hour

| | |
|--|--------------------------------------|
| End point title | Change in PT from baseline to 1 hour |
| End point description: Change in clotting factors from baseline to 1 hour | |
| End point type | Secondary |
| End point timeframe: 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 16 | | |
| Units: seconds | | | | |
| median (inter-quartile range (Q1-Q3)) | -4 (-6.1 to -2.1) | -2.6 (-4.85 to -1.3) | | |

Statistical analyses

| | |
|---|--------------------------------------|
| Statistical analysis title | Change in PT from baseline to 1 hour |
| Statistical analysis description: Difference in change between groups and 95% CIs. | |
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 35 |
| Analysis specification | Pre-specified |
| Analysis type | |
| Parameter estimate | Median difference (net) |
| Point estimate | 1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.94 |
| upper limit | 3.94 |

Secondary: Change in PT from baseline to 24 hours

| | |
|---|--|
| End point title | Change in PT from baseline to 24 hours |
| End point description: | |
| Difference between groups in change from baseline to 24 hours | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|-----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: seconds | | | | |
| median (inter-quartile range (Q1-Q3)) | -4.45 (-6.6 to -2.75) | -3.9 (-6.1 to -1.9) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[5] |
| Parameter estimate | Median difference (net) |
| Point estimate | 1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.5 |
| upper limit | 4.5 |

Notes:

[5] - Descriptive

Secondary: Change in APTT from baseline to 1 hour

| | |
|-----------------|--|
| End point title | Change in APTT from baseline to 1 hour |
|-----------------|--|

End point description:

Change in clotting factors at 1 hour

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 hour

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|-----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 15 | | |
| Units: seconds | | | | |
| median (inter-quartile range (Q1-Q3)) | -12.9 (-40.7 to -6.4) | -4.2 (-16.8 to 0.1) | | |

Statistical analyses

| | |
|----------------------------|--|
| Statistical analysis title | Change in APPT from baseline to 1 hour |
|----------------------------|--|

Statistical analysis description:

Median change(95% CI)

| | |
|-------------------|-------------------------------------|
| Comparison groups | FFP per protocol v PCC per protocol |
|-------------------|-------------------------------------|

| | |
|---|----|
| Number of subjects included in analysis | 34 |
|---|----|

| | |
|------------------------|---------------|
| Analysis specification | Pre-specified |
|------------------------|---------------|

| | |
|---------------|----------------------|
| Analysis type | other ^[6] |
|---------------|----------------------|

| | |
|--------------------|-------------------------|
| Parameter estimate | Median difference (net) |
|--------------------|-------------------------|

| | |
|----------------|-----|
| Point estimate | 8.7 |
|----------------|-----|

Confidence interval

| | |
|-------|------|
| level | 95 % |
|-------|------|

| | |
|-------|---------|
| sides | 2-sided |
|-------|---------|

| | |
|-------------|-------|
| lower limit | -13.2 |
|-------------|-------|

| | |
|-------------|------|
| upper limit | 30.6 |
|-------------|------|

Notes:

[6] - Descriptive

Secondary: Change in APTT from baseline to 24 hours

| | |
|-----------------|--|
| End point title | Change in APTT from baseline to 24 hours |
|-----------------|--|

End point description:

Change in clotting factors at 24 hours

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 hours

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|------------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 13 | | |
| Units: seconds | | | | |
| median (inter-quartile range (Q1-Q3)) | -30.55 (-49.4 to -7.1) | -7.9 (-23.9 to -6.1) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 29 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[7] |
| Parameter estimate | Median difference (net) |
| Point estimate | 28.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.19 |
| upper limit | 57.39 |

Notes:

[7] - Descriptive

Secondary: Change in fibrinogen at 1 hour

| | |
|--------------------------------------|--------------------------------|
| End point title | Change in fibrinogen at 1 hour |
| End point description: | |
| Change in clotting factors at 1 hour | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: g/L | | | | |
| median (inter-quartile range (Q1-Q3)) | 0.34 (0.2 to 0.6) | 0.01 (-0.1 to 0.26) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[8] |
| Parameter estimate | Median difference (net) |
| Point estimate | -0.33 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.59 |
| upper limit | -0.07 |

Notes:

[8] - Descriptive

Secondary: Change in fibrinogen at 24 hours

| | |
|------------------------|----------------------------------|
| End point title | Change in fibrinogen at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: g/L | | | | |
| median (inter-quartile range (Q1-Q3)) | 1.85 (1.19 to 2.57) | 1.7 (1.06 to 2.08) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[9] |
| Parameter estimate | Median difference (net) |
| Point estimate | -0.12 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.04 |
| upper limit | 0.8 |

Notes:

[9] - Decriptive

Secondary: Change in D-Dimer at 1 hour

| | |
|-----------------|-----------------------------|
| End point title | Change in D-Dimer at 1 hour |
|-----------------|-----------------------------|

| |
|------------------------|
| End point description: |
|------------------------|

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

| |
|----------------------|
| End point timeframe: |
|----------------------|

| |
|--------|
| 1 hour |
|--------|

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|-----------------------|-----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: mg/L FEU | | | | |
| median (inter-quartile range (Q1-Q3)) | -0.13 (-0.93 to 0.05) | -0.04 (-0.18 to 0.27) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | PCC per protocol v FFP per protocol |
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[10] |
| Parameter estimate | Median difference (net) |
| Point estimate | 0.09 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.31 |
| upper limit | 0.49 |

Notes:

[10] - Descriptive

Secondary: Change in D-Dimer at 24 hours

| | |
|-----------------|-------------------------------|
| End point title | Change in D-Dimer at 24 hours |
|-----------------|-------------------------------|

| |
|------------------------|
| End point description: |
|------------------------|

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

| |
|----------------------|
| End point timeframe: |
|----------------------|

| |
|----------|
| 24 hours |
|----------|

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|------------------------|-----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: mg/L FEU | | | | |
| median (inter-quartile range (Q1-Q3)) | -0.08 (-0.68 to -0.01) | -0.04 (-0.36 to 0.05) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[11] |
| Parameter estimate | Median difference (net) |
| Point estimate | 0.05 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.5 |
| upper limit | 0.6 |

Notes:

[11] - Descriptive

Secondary: Change in Factor II at 1 hour

| | |
|------------------------|-------------------------------|
| End point title | Change in Factor II at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 11.4 (4.5 to 16.3) | 22.4 (20.3 to 27.3) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[12] |
| Parameter estimate | Median difference (net) |
| Point estimate | 11 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 2.86 |
| upper limit | 19.14 |

Notes:

[12] - Descriptive

Secondary: Change in Factor II at 24 hours

| | |
|------------------------|---------------------------------|
| End point title | Change in Factor II at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 21.1 (3.55 to 28.8) | 21.45 (11.2 to 31.9) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[13] |
| Parameter estimate | Median difference (net) |
| Point estimate | -4.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -22.82 |
| upper limit | 13.82 |

Notes:

[13] - Descriptive

Secondary: Change in Factor V at 1 hour

| | |
|-----------------|------------------------------|
| End point title | Change in Factor V at 1 hour |
|-----------------|------------------------------|

| |
|------------------------|
| End point description: |
|------------------------|

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

| |
|----------------------|
| End point timeframe: |
|----------------------|

| |
|--------|
| 1 hour |
|--------|

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 26.2 (12.8 to 40.3) | 0.3 (-2 to 6.6) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[14] |
| Parameter estimate | Median difference (net) |
| Point estimate | -25.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -38.4 |
| upper limit | -13.4 |

Notes:

[14] - Descriptive

Secondary: Change in factor V at 24 hours

| | |
|-----------------|--------------------------------|
| End point title | Change in factor V at 24 hours |
|-----------------|--------------------------------|

| |
|------------------------|
| End point description: |
|------------------------|

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

| |
|----------------------|
| End point timeframe: |
|----------------------|

| |
|----------|
| 24 hours |
|----------|

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 59.3 (28.2 to 82.25) | 33.45 (15.3 to 55.9) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[15] |
| Parameter estimate | Median difference (net) |
| Point estimate | -19 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -51.6 |
| upper limit | 13.6 |

Notes:

[15] - Descriptive

Secondary: Change in factor VII at 1 hour

| | |
|------------------------|--------------------------------|
| End point title | Change in factor VII at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 16.7 (8 to 28.2) | 16.4 (12.5 to 23.8) | | |

Statistical analyses

| | |
|-----------------------------------|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[16] |
| Parameter estimate | Median difference (net) |
| Point estimate | -0.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -10.49 |
| upper limit | 9.89 |

Notes:

[16] - Descriptive

Secondary: Change in Factor VII at 24 hours

| | |
|------------------------|----------------------------------|
| End point title | Change in Factor VII at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|-----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | -4.55 (-10.7 to 17.5) | 8.2 (-14.1 to 13.5) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 11.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -9.65 |
| upper limit | 31.85 |

Secondary: Change in Factor VIII at 1 hour

| | |
|-----------------|---------------------------------|
| End point title | Change in Factor VIII at 1 hour |
|-----------------|---------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 hour

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 8.4 (-14.3 to 40.8) | 1 (-7.3 to 31.7) | | |

Statistical analyses

| | |
|-----------------------------------|---|
| Statistical analysis title | Difference in change between treatment groups |
|-----------------------------------|---|

| | |
|-------------------|-------------------------------------|
| Comparison groups | FFP per protocol v PCC per protocol |
|-------------------|-------------------------------------|

| | |
|---|----|
| Number of subjects included in analysis | 36 |
|---|----|

| | |
|------------------------|---------------|
| Analysis specification | Pre-specified |
|------------------------|---------------|

| | |
|---------------|-------|
| Analysis type | other |
|---------------|-------|

| | |
|--------------------|-----------------------|
| Parameter estimate | Mean difference (net) |
|--------------------|-----------------------|

| | |
|----------------|------|
| Point estimate | -7.4 |
|----------------|------|

Confidence interval

| | |
|-------|------|
| level | 95 % |
|-------|------|

| | |
|-------|---------|
| sides | 2-sided |
|-------|---------|

| | |
|-------------|--------|
| lower limit | -37.09 |
|-------------|--------|

| | |
|-------------|-------|
| upper limit | 22.29 |
|-------------|-------|

Secondary: Change in Factor VIII at 24 hours

| | |
|-----------------|-----------------------------------|
| End point title | Change in Factor VIII at 24 hours |
|-----------------|-----------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 hours

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|-------------------------|-----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 106.1 (79.65 to 121.05) | 87.45 (57.1 to 127.4) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean difference (net) |
| Point estimate | -10.7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -60.8 |
| upper limit | 39.4 |

Secondary: Change in Factor IX at 1 hour

| | |
|------------------------|-------------------------------|
| End point title | Change in Factor IX at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 7.2 (-8.6 to 24.9) | 14.9 (3.4 to 21) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 7.7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -10.73 |
| upper limit | 26.13 |

Secondary: Change in Factor IX at 24 hours

| | |
|------------------------|---------------------------------|
| End point title | Change in Factor IX at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 28.35 (6.5 to 40.2) | 27.1 (4 to 40.4) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | PCC per protocol v FFP per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -0.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -24.02 |
| upper limit | 23.42 |

Secondary: Change in Factor X at 1 hour

| | |
|-----------------|------------------------------|
| End point title | Change in Factor X at 1 hour |
|-----------------|------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 hour

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 11.6 (4.8 to 18.1) | 20.9 (17.2 to 26.5) | | |

Statistical analyses

| | |
|----------------------------|---|
| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|

| | |
|-------------------|-------------------------------------|
| Comparison groups | FFP per protocol v PCC per protocol |
|-------------------|-------------------------------------|

| | |
|---|----|
| Number of subjects included in analysis | 36 |
|---|----|

| | |
|------------------------|---------------|
| Analysis specification | Pre-specified |
|------------------------|---------------|

| | |
|---------------|-------|
| Analysis type | other |
|---------------|-------|

| | |
|--------------------|-------------------------|
| Parameter estimate | Median difference (net) |
|--------------------|-------------------------|

| | |
|----------------|-----|
| Point estimate | 9.3 |
|----------------|-----|

Confidence interval

| | |
|-------|------|
| level | 95 % |
|-------|------|

| | |
|-------|---------|
| sides | 2-sided |
|-------|---------|

| | |
|-------------|------|
| lower limit | 0.71 |
|-------------|------|

| | |
|-------------|-------|
| upper limit | 17.89 |
|-------------|-------|

Secondary: Change in Factor X at 24 hours

| | |
|-----------------|--------------------------------|
| End point title | Change in Factor X at 24 hours |
|-----------------|--------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 hours

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 22.25 (6.3 to 27) | 22.45 (9.3 to 29.8) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean difference (net) |
| Point estimate | -3.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -20.5 |
| upper limit | 13.7 |

Secondary: Change in Factor XI at 1 hour

| | |
|------------------------|-------------------------------|
| End point title | Change in Factor XI at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 8.4 (3.1 to 27.1) | 0 (-3.9 to 6.8) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -8.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -20.9 |
| upper limit | 4.1 |

Secondary: Change in Factor XI at 24 hours

| | |
|------------------------|---------------------------------|
| End point title | Change in Factor XI at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 20.75 (9.4 to 38.3) | 5.65 (0 to 21.5) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -16.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -35.84 |
| upper limit | 3.04 |

Secondary: Change in Factor XII at 1 hour

| | |
|-----------------|--------------------------------|
| End point title | Change in Factor XII at 1 hour |
|-----------------|--------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 hour

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: U/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 10.5 (1.5 to 17.4) | -2.2 (-7.2 to 3.5) | | |

Statistical analyses

| | |
|-----------------------------------|---|
| Statistical analysis title | Difference in change between treatment groups |
|-----------------------------------|---|

| | |
|-------------------|-------------------------------------|
| Comparison groups | FFP per protocol v PCC per protocol |
|-------------------|-------------------------------------|

| | |
|---|----|
| Number of subjects included in analysis | 36 |
|---|----|

| | |
|------------------------|---------------|
| Analysis specification | Pre-specified |
|------------------------|---------------|

| | |
|---------------|-------|
| Analysis type | other |
|---------------|-------|

| | |
|--------------------|-----------------------|
| Parameter estimate | Mean difference (net) |
|--------------------|-----------------------|

| | |
|----------------|-------|
| Point estimate | -12.7 |
|----------------|-------|

Confidence interval

| | |
|-------|------|
| level | 95 % |
|-------|------|

| | |
|-------|---------|
| sides | 2-sided |
|-------|---------|

| | |
|-------------|--------|
| lower limit | -24.46 |
|-------------|--------|

| | |
|-------------|-------|
| upper limit | -0.94 |
|-------------|-------|

Secondary: Change in Factor XII at 24 hours

| | |
|-----------------|----------------------------------|
| End point title | Change in Factor XII at 24 hours |
|-----------------|----------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 hours

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: U/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 21.5 (-0.5 to 32.7) | 10.75 (0.3 to 24.2) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Mean difference (net) |
| Point estimate | -13.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -34.34 |
| upper limit | 8.14 |

Secondary: Change in Factor XIII at 1 hour

| | |
|------------------------|---------------------------------|
| End point title | Change in Factor XIII at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 10.5 (2.7 to 19.1) | -1.8 (-5.5 to 3.2) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -12.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -22.26 |
| upper limit | -2.34 |

Secondary: Change in Factor XIII at 24 hours

| | |
|------------------------|-----------------------------------|
| End point title | Change in Factor XIII at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 7.05 (4.1 to 14.3) | 0.9 (-16.3 to 12.3) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | PCC per protocol v FFP per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -9.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -24.02 |
| upper limit | 5.82 |

Secondary: Change in VWF antigen at 1 hour

| | |
|-----------------|---------------------------------|
| End point title | Change in VWF antigen at 1 hour |
|-----------------|---------------------------------|

| |
|------------------------|
| End point description: |
|------------------------|

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

| |
|----------------------|
| End point timeframe: |
|----------------------|

| |
|--------|
| 1 hour |
|--------|

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 16 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 1.7 (-14.9 to 28.6) | 20.35 (-5.75 to 39) | | |

Statistical analyses

| | |
|----------------------------|---|
| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|

| | |
|-------------------|-------------------------------------|
| Comparison groups | FFP per protocol v PCC per protocol |
|-------------------|-------------------------------------|

| | |
|---|----|
| Number of subjects included in analysis | 35 |
|---|----|

| | |
|------------------------|---------------|
| Analysis specification | Pre-specified |
|------------------------|---------------|

| | |
|---------------|-------|
| Analysis type | other |
|---------------|-------|

| | |
|--------------------|-------------------------|
| Parameter estimate | Median difference (net) |
|--------------------|-------------------------|

| | |
|----------------|------|
| Point estimate | 18.9 |
|----------------|------|

| |
|---------------------|
| Confidence interval |
|---------------------|

| | |
|-------|------|
| level | 95 % |
|-------|------|

| | |
|-------|---------|
| sides | 2-sided |
|-------|---------|

| | |
|-------------|--------|
| lower limit | -11.96 |
|-------------|--------|

| | |
|-------------|-------|
| upper limit | 49.76 |
|-------------|-------|

Secondary: Change in VWF antigen at 24 hours

| | |
|-----------------|-----------------------------------|
| End point title | Change in VWF antigen at 24 hours |
|-----------------|-----------------------------------|

| |
|------------------------|
| End point description: |
|------------------------|

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

| |
|----------------------|
| End point timeframe: |
|----------------------|

| |
|----------|
| 24 hours |
|----------|

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|------------------------|-----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 69.65 (5.45 to 119.25) | 83.95 (53.9 to 124.4) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 16.6 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -41.51 |
| upper limit | 74.71 |

Secondary: Change in VWF activity at 1 hour

| | |
|------------------------|----------------------------------|
| End point title | Change in VWF activity at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 16 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 20.1 (-0.9 to 42.7) | 17.35 (-0.5 to 88.6) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 35 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 0 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -52.59 |
| upper limit | 52.59 |

Secondary: Change in VWF activity at 24 hours

| | |
|------------------------|------------------------------------|
| End point title | Change in VWF activity at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|------------------------|-----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 87.65 (29.55 to 129.7) | 101.6 (82.2 to 124.2) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 9.7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -50.45 |
| upper limit | 69.85 |

Secondary: Change in AT activity at 1 hour

| | |
|-----------------|---------------------------------|
| End point title | Change in AT activity at 1 hour |
|-----------------|---------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 hour

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 18 | 16 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 9.9 (4.5 to 12.9) | 0.5 (-2 to 3.7) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 34 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -13.96 |
| upper limit | -4.04 |

Secondary: Change in AT activity at 24 hours

| | |
|-----------------|-----------------------------------|
| End point title | Change in AT activity at 24 hours |
|-----------------|-----------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 hours

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 22.25 (8.1 to 29.4) | 14.75 (4.7 to 18.1) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -7.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -18.34 |
| upper limit | 3.34 |

Secondary: Change in PC activity at 1 hour

| | |
|------------------------|---------------------------------|
| End point title | Change in PC activity at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 11.2 (5.8 to 21) | 19.9 (9.1 to 29) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 8.7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.72 |
| upper limit | 18.12 |

Secondary: Change in PC activity at 24 hours

| | |
|------------------------|-----------------------------------|
| End point title | Change in PC activity at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|------------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 21.25 (14.05 to 36.65) | 18.85 (-0.2 to 33.8) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -5.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -24.55 |
| upper limit | 14.35 |

Secondary: Change in TAT at 1 hour

| | |
|-----------------|-------------------------|
| End point title | Change in TAT at 1 hour |
|-----------------|-------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 hour

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 16 | | |
| Units: µg/L | | | | |
| median (inter-quartile range (Q1-Q3)) | 0 (0 to 0.3) | 0 (0 to 0.2) | | |

Statistical analyses

| | |
|----------------------------|---|
| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|

| | |
|-------------------|-------------------------------------|
| Comparison groups | FFP per protocol v PCC per protocol |
|-------------------|-------------------------------------|

| | |
|---|----|
| Number of subjects included in analysis | 32 |
|---|----|

| | |
|------------------------|---------------|
| Analysis specification | Pre-specified |
|------------------------|---------------|

| | |
|---------------|-------|
| Analysis type | other |
|---------------|-------|

| | |
|--------------------|-------------------------|
| Parameter estimate | Median difference (net) |
|--------------------|-------------------------|

| | |
|----------------|---|
| Point estimate | 0 |
|----------------|---|

Confidence interval

| | |
|-------|------|
| level | 95 % |
|-------|------|

| | |
|-------|---------|
| sides | 2-sided |
|-------|---------|

| | |
|-------------|-------|
| lower limit | -3.79 |
|-------------|-------|

| | |
|-------------|------|
| upper limit | 3.79 |
|-------------|------|

Secondary: Change in TAT at 24 hours

| | |
|-----------------|---------------------------|
| End point title | Change in TAT at 24 hours |
|-----------------|---------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 hours

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 14 | 13 | | |
| Units: µg/L | | | | |
| median (inter-quartile range (Q1-Q3)) | -5 (-12.4 to 0) | -2.4 (-12.1 to 0) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 27 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 1.6 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -8.85 |
| upper limit | 12.05 |

Secondary: Change in HMWK at 1 hour

| | |
|------------------------|--------------------------|
| End point title | Change in HMWK at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 15 | | |
| Units: U/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | -3.15 (-4.1 to 02) | 10.9 (-2.6 to 23.3) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 31 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -10.29 |
| upper limit | 24.29 |

Secondary: Change in HMWK at 24 hours

| | |
|------------------------|----------------------------|
| End point title | Change in HMWK at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|-----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 14 | 12 | | |
| Units: U/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 6.3 (-7.9 to 21.4) | 14.6 (-9.75 to 24.45) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 26 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (final values) |
| Point estimate | 8.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -17.3 |
| upper limit | 34.1 |

Secondary: Change in PRK at 1 hour

| | |
|-----------------|-------------------------|
| End point title | Change in PRK at 1 hour |
|-----------------|-------------------------|

| |
|------------------------|
| End point description: |
|------------------------|

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

| |
|----------------------|
| End point timeframe: |
|----------------------|

| |
|--------|
| 1 hour |
|--------|

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 15 | | |
| Units: U/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 10.3 (-2.85 to 18.1) | -4 (-12 to 14.5) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 31 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -17.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -35.7 |
| upper limit | 0.9 |

Secondary: Change in PRK at 24 hours

| | |
|-----------------|---------------------------|
| End point title | Change in PRK at 24 hours |
|-----------------|---------------------------|

| |
|------------------------|
| End point description: |
|------------------------|

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

| |
|----------------------|
| End point timeframe: |
|----------------------|

| |
|----------|
| 24 hours |
|----------|

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|-----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 14 | 12 | | |
| Units: U/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 5.55 (-6.4 to 25.7) | -2.8 (-34.75 to 13.3) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 26 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -12.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -44.12 |
| upper limit | 19.52 |

Secondary: Change in C1-inhibitor at 1 hour

| | |
|------------------------|----------------------------------|
| End point title | Change in C1-inhibitor at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 16 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 7.2 (-6.4 to 13.1) | 2.3 (-7.55 to 7.1) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 35 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -7.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -19.62 |
| upper limit | 4.82 |

Secondary: Change in C1-inhibitor at 24 hours

| | |
|------------------------|------------------------------------|
| End point title | Change in C1-inhibitor at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 34.15 (8.1 to 45.95) | 24.2 (10.9 to 40.2) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -4.6 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -29.15 |
| upper limit | 19.95 |

Secondary: change in a2-antiplasmin at 1 hour

| | |
|-----------------|------------------------------------|
| End point title | change in a2-antiplasmin at 1 hour |
|-----------------|------------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 hour

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 8.4 (4.2 to 16.7) | -1 (-2.9 to 7.2) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -9.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -17.15 |
| upper limit | -1.65 |

Secondary: change in a2-antiplasmin at 24 hours

| | |
|-----------------|--------------------------------------|
| End point title | change in a2-antiplasmin at 24 hours |
|-----------------|--------------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 hours

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|-----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 34.85 (16.5 to 43.25) | 23.95 (6.3 to 36) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -11.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -35.82 |
| upper limit | 13.42 |

Secondary: Change in plasminogen at 1 hour

| | |
|------------------------|---------------------------------|
| End point title | Change in plasminogen at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 17 | | |
| Units: U/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 6.7 (1.3 to 11.7) | -1 (-4.2 to 1) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -7.7 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -13.31 |
| upper limit | -2.09 |

Secondary: Change in plasminogen at 24 hours

| | |
|------------------------|-----------------------------------|
| End point title | Change in plasminogen at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|-----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 14 | | |
| Units: U/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 16.35 (8.25 to 22.85) | 2.6 (-3.8 to 10.5) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 30 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -12.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -22.05 |
| upper limit | -2.15 |

Secondary: Change in tPA:Ag activity at 1 hour

| | |
|-----------------|-------------------------------------|
| End point title | Change in tPA:Ag activity at 1 hour |
|-----------------|-------------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 hour

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 16 | | |
| Units: µg/L | | | | |
| median (inter-quartile range (Q1-Q3)) | -0.3 (-1.7 to 1.1) | 0 (-1.35 to 1.1) | | |

Statistical analyses

| | |
|----------------------------|---|
| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|

| | |
|-------------------|-------------------------------------|
| Comparison groups | FFP per protocol v PCC per protocol |
|-------------------|-------------------------------------|

| | |
|---|----|
| Number of subjects included in analysis | 35 |
|---|----|

| | |
|------------------------|---------------|
| Analysis specification | Pre-specified |
|------------------------|---------------|

| | |
|---------------|-------|
| Analysis type | other |
|---------------|-------|

| | |
|--------------------|-------------------------|
| Parameter estimate | Median difference (net) |
|--------------------|-------------------------|

| | |
|----------------|-----|
| Point estimate | 0.3 |
|----------------|-----|

Confidence interval

| | |
|-------|------|
| level | 95 % |
|-------|------|

| | |
|-------|---------|
| sides | 2-sided |
|-------|---------|

| | |
|-------------|------|
| lower limit | -1.1 |
|-------------|------|

| | |
|-------------|-----|
| upper limit | 1.7 |
|-------------|-----|

Secondary: Change in tPA:Ag at 24 hours

| | |
|-----------------|------------------------------|
| End point title | Change in tPA:Ag at 24 hours |
|-----------------|------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 hours

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 13 | | |
| Units: µg/L | | | | |
| median (inter-quartile range (Q1-Q3)) | 0.2 (-1.4 to 3.95) | -1.5 (-3.4 to 0) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 29 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -1.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.36 |
| upper limit | 1.76 |

Secondary: Change in Prothrombin F.1+2 at 1 hour

| | |
|------------------------|---------------------------------------|
| End point title | Change in Prothrombin F.1+2 at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 16 | | |
| Units: pM | | | | |
| median (inter-quartile range (Q1-Q3)) | 13 (0 to 219.5) | 0 (-233.5 to 137) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | PCC per protocol v FFP per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 32 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -26 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -244.38 |
| upper limit | 192.38 |

Secondary: Change in Prothrombin F.1+2 at 24 hours

| | |
|------------------------|---|
| End point title | Change in Prothrombin F.1+2 at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|-----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 14 | 13 | | |
| Units: pM | | | | |
| median (inter-quartile range (Q1-Q3)) | -524.5 (-920 to -317) | -651 (-934 to -398) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 27 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -153 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -542.95 |
| upper limit | 236.95 |

Secondary: Change in PAP at 1 hour

| | |
|-----------------|-------------------------|
| End point title | Change in PAP at 1 hour |
|-----------------|-------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 hour

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 18 | 16 | | |
| Units: pg/mL | | | | |
| median (inter-quartile range (Q1-Q3)) | 104 (-34 to 336) | -54 (-139 to 38.5) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 34 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -157 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -386.64 |
| upper limit | 72.64 |

Secondary: change in PAP at 24 hours

| | |
|-----------------|---------------------------|
| End point title | change in PAP at 24 hours |
|-----------------|---------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 hours

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 15 | 13 | | |
| Units: pg/mL | | | | |
| median (inter-quartile range (Q1-Q3)) | 179 (-73 to 391) | -49 (-220 to 320) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -228 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -593.96 |
| upper limit | 137.96 |

Secondary: Change in TAFI at 1 hour

| | |
|------------------------|--------------------------|
| End point title | Change in TAFI at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 19 | 16 | | |
| Units: ng/mL | | | | |
| median (inter-quartile range (Q1-Q3)) | 9 (3 to 16) | 4 (-1 to 7) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 35 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -11 |
| upper limit | 1 |

Secondary: Change in TAFI at 24 hours

| | |
|------------------------|----------------------------|
| End point title | Change in TAFI at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 13 | | |
| Units: ng/mL | | | | |
| median (inter-quartile range (Q1-Q3)) | 13 (7.5 to 21.5) | 8 (-2 to 11) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | PCC per protocol v FFP per protocol |
| Number of subjects included in analysis | 29 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -15.96 |
| upper limit | 5.96 |

Secondary: Change in thrombomodulin at 1 hour

| | |
|-----------------|------------------------------------|
| End point title | Change in thrombomodulin at 1 hour |
|-----------------|------------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 hour

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 18 | 16 | | |
| Units: pg/mL | | | | |
| median (inter-quartile range (Q1-Q3)) | 100 (30 to 524) | 183.5 (67 to 406.5) | | |

Statistical analyses

| | |
|----------------------------|---|
| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|

| | |
|-------------------|-------------------------------------|
| Comparison groups | FFP per protocol v PCC per protocol |
|-------------------|-------------------------------------|

| | |
|---|----|
| Number of subjects included in analysis | 34 |
|---|----|

| | |
|------------------------|---------------|
| Analysis specification | Pre-specified |
|------------------------|---------------|

| | |
|---------------|-------|
| Analysis type | other |
|---------------|-------|

| | |
|--------------------|-------------------------|
| Parameter estimate | Median difference (net) |
|--------------------|-------------------------|

| | |
|----------------|-----|
| Point estimate | 146 |
|----------------|-----|

Confidence interval

| | |
|-------|------|
| level | 95 % |
|-------|------|

| | |
|-------|---------|
| sides | 2-sided |
|-------|---------|

| | |
|-------------|---------|
| lower limit | -131.72 |
|-------------|---------|

| | |
|-------------|--------|
| upper limit | 423.72 |
|-------------|--------|

Secondary: Change in thrombomodulin at 24 hours

| | |
|-----------------|--------------------------------------|
| End point title | Change in thrombomodulin at 24 hours |
|-----------------|--------------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 hours

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 15 | 13 | | |
| Units: pg/mL | | | | |
| median (inter-quartile range (Q1-Q3)) | 38 (-67 to 251) | 70 (3 to 169) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 32 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -162.33 |
| upper limit | 226.33 |

Secondary: Change in Tissue Factor at 1 hour

| | |
|------------------------|-----------------------------------|
| End point title | Change in Tissue Factor at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 17 | 16 | | |
| Units: pg/mL | | | | |
| median (inter-quartile range (Q1-Q3)) | 0.8 (-0.7 to 8.4) | 0.05 (-2.05 to 1.35) | | |

Statistical analyses

| | |
|----------------------------|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 33 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -0.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.79 |
| upper limit | 4.19 |

Secondary: Change in Tissue Factor at 24 hours

| | |
|------------------------|-------------------------------------|
| End point title | Change in Tissue Factor at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 15 | 13 | | |
| Units: pg/mL | | | | |
| median (inter-quartile range (Q1-Q3)) | 1 (-0.5 to 2.2) | 0 (-2.1 to 0.4) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.21 |
| upper limit | 1.21 |

Secondary: Change in sEPCR at 1 hour

| | |
|-----------------|---------------------------|
| End point title | Change in sEPCR at 1 hour |
|-----------------|---------------------------|

| |
|------------------------|
| End point description: |
|------------------------|

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

| |
|----------------------|
| End point timeframe: |
|----------------------|

| |
|--------|
| 1 hour |
|--------|

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 18 | 16 | | |
| Units: ng/mL | | | | |
| median (inter-quartile range (Q1-Q3)) | 0 (0 to 749) | 0 (-1319 to 713.5) | | |

Statistical analyses

| | |
|-----------------------------------|---|
| Statistical analysis title | Difference in change between treatment groups |
|-----------------------------------|---|

| | |
|-------------------|-------------------------------------|
| Comparison groups | FFP per protocol v PCC per protocol |
|-------------------|-------------------------------------|

| | |
|---|----|
| Number of subjects included in analysis | 34 |
|---|----|

| | |
|------------------------|---------------|
| Analysis specification | Pre-specified |
|------------------------|---------------|

| | |
|---------------|-------|
| Analysis type | other |
|---------------|-------|

| | |
|--------------------|-------------------------|
| Parameter estimate | Median difference (net) |
|--------------------|-------------------------|

| | |
|----------------|---|
| Point estimate | 0 |
|----------------|---|

| |
|---------------------|
| Confidence interval |
|---------------------|

| | |
|-------|------|
| level | 95 % |
|-------|------|

| | |
|-------|---------|
| sides | 2-sided |
|-------|---------|

| | |
|-------------|----------|
| lower limit | -1129.98 |
|-------------|----------|

| | |
|-------------|---------|
| upper limit | 1129.98 |
|-------------|---------|

Secondary: Change in sEPCR at 24 hours

| | |
|-----------------|-----------------------------|
| End point title | Change in sEPCR at 24 hours |
|-----------------|-----------------------------|

| |
|------------------------|
| End point description: |
|------------------------|

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

| |
|----------------------|
| End point timeframe: |
|----------------------|

| |
|----------|
| 24 hours |
|----------|

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 15 | 13 | | |
| Units: ng/mL | | | | |
| median (inter-quartile range (Q1-Q3)) | 0 (-1167 to 0) | -362 (-2189 to 167) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 362 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2202.82 |
| upper limit | 1478.82 |

Secondary: Change in TG-ETP at 1 hour

| | |
|------------------------|----------------------------|
| End point title | Change in TG-ETP at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 17 | 17 | | |
| Units: nM Thrombin | | | | |
| median (inter-quartile range (Q1-Q3)) | 350 (-237 to 667) | 159 (-352 to 714) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 34 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 191 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -765.84 |
| upper limit | 383.84 |

Secondary: Change in TG-ETP at 24 hours

| | |
|------------------------|------------------------------|
| End point title | Change in TG-ETP at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 14 | 14 | | |
| Units: nM Thrombin | | | | |
| median (inter-quartile range (Q1-Q3)) | 581.5 (112 to 961) | 686 (116 to 1407) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 27 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -763.25 |
| upper limit | 817.25 |

Secondary: Change in TG- Peak thrombin at 1 hour

| | |
|-----------------|---------------------------------------|
| End point title | Change in TG- Peak thrombin at 1 hour |
|-----------------|---------------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 hour

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 17 | 17 | | |
| Units: nM Thrombin | | | | |
| median (inter-quartile range (Q1-Q3)) | 88 (-48 to 118) | 6 (-57 to 64) | | |

Statistical analyses

| | |
|-----------------------------------|---|
| Statistical analysis title | Difference in change between treatment groups |
|-----------------------------------|---|

| | |
|-------------------|-------------------------------------|
| Comparison groups | FFP per protocol v PCC per protocol |
|-------------------|-------------------------------------|

| | |
|---|----|
| Number of subjects included in analysis | 34 |
|---|----|

| | |
|------------------------|---------------|
| Analysis specification | Pre-specified |
|------------------------|---------------|

| | |
|---------------|-------|
| Analysis type | other |
|---------------|-------|

| | |
|--------------------|-------------------------|
| Parameter estimate | Median difference (net) |
|--------------------|-------------------------|

| | |
|----------------|-----|
| Point estimate | -82 |
|----------------|-----|

Confidence interval

| | |
|-------|------|
| level | 95 % |
|-------|------|

| | |
|-------|---------|
| sides | 2-sided |
|-------|---------|

| | |
|-------------|---------|
| lower limit | -194.68 |
|-------------|---------|

| | |
|-------------|-------|
| upper limit | 30.68 |
|-------------|-------|

Secondary: Change in TG- Peak thrombin at 24 hours

| | |
|-----------------|---|
| End point title | Change in TG- Peak thrombin at 24 hours |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 hours

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 14 | 14 | | |
| Units: nM Thrombin | | | | |
| median (inter-quartile range (Q1-Q3)) | 82.5 (-29 to 166) | 53 (-7 to 223) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -14 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -141.4 |
| upper limit | 113.4 |

Secondary: Change in TG- lag time at 1 hour

| | |
|------------------------|----------------------------------|
| End point title | Change in TG- lag time at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|-----------------------|-----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 17 | 17 | | |
| Units: minutes | | | | |
| median (inter-quartile range (Q1-Q3)) | -1.33 (-5.61 to 0.44) | -0.45 (-0.88 to 0.33) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | FFP per protocol v PCC per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 34 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 0.88 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.51 |
| upper limit | 4.27 |

Secondary: Change in TG - lag time at 24 hours

| | |
|------------------------|-------------------------------------|
| End point title | Change in TG - lag time at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|-----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 14 | 14 | | |
| Units: minutes | | | | |
| median (inter-quartile range (Q1-Q3)) | -1.69 (-5.61 to 1.11) | 0.34 (-0.22 to 2) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 2.78 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.75 |
| upper limit | 6.31 |

Secondary: Change in TG- time to peak at 1 hour

| | |
|-----------------|--------------------------------------|
| End point title | Change in TG- time to peak at 1 hour |
|-----------------|--------------------------------------|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 hour

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|-----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 17 | 17 | | |
| Units: minutes | | | | |
| median (inter-quartile range (Q1-Q3)) | -2.83 (-9.56 to 0.61) | 0.67 (-0.89 to 2) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | PCC per protocol v FFP per protocol |
| Number of subjects included in analysis | 34 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 3.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.88 |
| upper limit | 7.88 |

Secondary: Change in TG- time to peak at 24 hours

| | |
|-----------------|--|
| End point title | Change in TG- time to peak at 24 hours |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 hours

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|-----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 14 | 14 | | |
| Units: minutes | | | | |
| median (inter-quartile range (Q1-Q3)) | -3.44 (-9.33 to 1.89) | 1.11 (-0.67 to 3.22) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|---|---|
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 28 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 4.71 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.97 |
| upper limit | 10.39 |

Secondary: Change in Free PS antigen at 1 hour

| | |
|------------------------|-------------------------------------|
| End point title | Change in Free PS antigen at 1 hour |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 1 hour | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 18 | 16 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 8.35 (4.4 to 11.7) | 13 (6.55 to 16.05) | | |

Statistical analyses

| Statistical analysis title | Difference in change between treatment groups |
|----------------------------|---|
| Comparison groups | PCC per protocol v FFP per protocol |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 34 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | 5.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.03 |
| upper limit | 10.23 |

Secondary: Change in Free PS antigen at 24 hours

| | |
|------------------------|---------------------------------------|
| End point title | Change in Free PS antigen at 24 hours |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 hours | |

| End point values | FFP per protocol | PCC per protocol | | |
|---------------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 16 | 13 | | |
| Units: IU/dL | | | | |
| median (inter-quartile range (Q1-Q3)) | 15.6 (-2.1 to 24.55) | 12.2 (4.6 to 19.3) | | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Difference in change between treatment groups |
| Comparison groups | FFP per protocol v PCC per protocol |
| Number of subjects included in analysis | 29 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Median difference (net) |
| Point estimate | -3.1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -16.88 |
| upper limit | 10.68 |

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected from one hour after receiving study intervention until 90 days following intervention or death, whichever occurs first.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 23.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---|
| Reporting group title | Fresh Frozen Plasma (FFP) Safety population |
|-----------------------|---|

Reporting group description:

All consenting patients who bled and received FFP regardless of whether they were randomised.

| | |
|-----------------------|---|
| Reporting group title | Prothrombin Complex Concentrate (PCC) Safety population |
|-----------------------|---|

Reporting group description:

All consenting patients who bled and received PCC regardless of whether they were randomised.

| Serious adverse events | Fresh Frozen Plasma (FFP) Safety population | Prothrombin Complex Concentrate (PCC) Safety population | |
|---|---|---|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 9 / 26 (34.62%) | 5 / 29 (17.24%) | |
| number of deaths (all causes) | 1 | 1 | |
| number of deaths resulting from adverse events | 1 | 1 | |
| Investigations | | | |
| Raised INR | | | |
| subjects affected / exposed | 0 / 26 (0.00%) | 1 / 29 (3.45%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Lacunar infarction | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral infarction | | | |
| subjects affected / exposed | 2 / 26 (7.69%) | 0 / 29 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal cord ischaemia | | | |

| | | | |
|--|----------------|----------------|--|
| subjects affected / exposed | 0 / 26 (0.00%) | 1 / 29 (3.45%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mesenteric artery thrombosis | | | |
| subjects affected / exposed | 0 / 26 (0.00%) | 1 / 29 (3.45%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypotension | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Acute right ventricular failure | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulseless electrical activity | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Heart valve incompetence | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cardiac failure congestive | | | |
| subjects affected / exposed | 0 / 26 (0.00%) | 1 / 29 (3.45%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Heart failure | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |

| | | | |
|---|----------------|----------------|--|
| Malaise | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Multiorgan failure | | | |
| subjects affected / exposed | 0 / 26 (0.00%) | 1 / 29 (3.45%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Haemothorax | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest pain | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleuritic pain | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Fresh Frozen Plasma (FFP) Safety population | Prothrombin Complex Concentrate (PCC) Safety population | |
|---|---|---|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 21 / 26 (80.77%) | 22 / 29 (75.86%) | |

| | | | | |
|--------------------|--|----------------|-----------------|--|
| Vascular disorders | Hypotension | | | |
| | subjects affected / exposed | 2 / 26 (7.69%) | 1 / 29 (3.45%) | |
| | occurrences (all) | 2 | 1 | |
| | Thrombosis | | | |
| | subjects affected / exposed | 2 / 26 (7.69%) | 1 / 29 (3.45%) | |
| | occurrences (all) | 2 | 1 | |
| | Thrombophlebitis | | | |
| | subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| | occurrences (all) | 1 | 0 | |
| | Haematoma | | | |
| | subjects affected / exposed | 1 / 26 (3.85%) | 1 / 29 (3.45%) | |
| | occurrences (all) | 1 | 1 | |
| | Epistaxis | | | |
| | subjects affected / exposed | 0 / 26 (0.00%) | 1 / 29 (3.45%) | |
| | occurrences (all) | 0 | 1 | |
| | Haemorrhage | | | |
| | subjects affected / exposed | 1 / 26 (3.85%) | 1 / 29 (3.45%) | |
| | occurrences (all) | 1 | 1 | |
| | Peripheral artery aneurysm | | | |
| | subjects affected / exposed | 0 / 26 (0.00%) | 1 / 29 (3.45%) | |
| | occurrences (all) | 0 | 1 | |
| | Surgical and medical procedures | | | |
| | Tracheostomy | | | |
| | subjects affected / exposed | 1 / 26 (3.85%) | 3 / 29 (10.34%) | |
| | occurrences (all) | 1 | 3 | |
| | Cardiac pacemaker insertion | | | |
| | subjects affected / exposed | 0 / 26 (0.00%) | 1 / 29 (3.45%) | |
| | occurrences (all) | 0 | 1 | |
| | General disorders and administration site conditions | | | |
| | Fever | | | |
| | subjects affected / exposed | 2 / 26 (7.69%) | 1 / 29 (3.45%) | |
| | occurrences (all) | 2 | 1 | |
| | Asthenia | | | |
| | subjects affected / exposed | 1 / 26 (3.85%) | 1 / 29 (3.45%) | |
| | occurrences (all) | 1 | 1 | |

| | | | |
|---|------------------|------------------|--|
| Respiratory, thoracic and mediastinal disorders | | | |
| Pleural effusion | | | |
| subjects affected / exposed | 14 / 26 (53.85%) | 14 / 29 (48.28%) | |
| occurrences (all) | 15 | 15 | |
| Atelectasis | | | |
| subjects affected / exposed | 5 / 26 (19.23%) | 2 / 29 (6.90%) | |
| occurrences (all) | 5 | 2 | |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 2 / 29 (6.90%) | |
| occurrences (all) | 1 | 2 | |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 26 (0.00%) | 2 / 29 (6.90%) | |
| occurrences (all) | 0 | 2 | |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 26 (0.00%) | 3 / 29 (10.34%) | |
| occurrences (all) | 0 | 3 | |
| Respiratory failure | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 3 / 29 (10.34%) | |
| occurrences (all) | 1 | 3 | |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 26 (0.00%) | 1 / 29 (3.45%) | |
| occurrences (all) | 0 | 1 | |
| Investigations | | | |
| Liver function test abnormal | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 1 / 29 (3.45%) | |
| occurrences (all) | 1 | 1 | |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 26 (0.00%) | 1 / 29 (3.45%) | |
| occurrences (all) | 0 | 1 | |
| Blood lactic acid increased | | | |
| subjects affected / exposed | 1 / 26 (3.85%) | 0 / 29 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Lactic acidosis | | | |
| subjects affected / exposed | 0 / 26 (0.00%) | 1 / 29 (3.45%) | |
| occurrences (all) | 0 | 1 | |
| Thoracic cavity drainage | | | |

| | | | |
|--|----------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 26 (0.00%) 0 | 1 / 29 (3.45%) 1 | |
| Injury, poisoning and procedural complications Fall subjects affected / exposed occurrences (all) | 0 / 26 (0.00%) 0 | 1 / 29 (3.45%) 2 | |
| Cardiac perforation subjects affected / exposed occurrences (all) | 0 / 26 (0.00%) 0 | 1 / 29 (3.45%) 1 | |
| Cardiac disorders Pericardial effusion subjects affected / exposed occurrences (all) | 4 / 26 (15.38%) 4 | 1 / 29 (3.45%) 1 | |
| Pulmonary oedema subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 2 / 29 (6.90%) 2 | |
| Nervous system disorders Meningioma subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 0 / 29 (0.00%) 0 | |
| Seizure subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 0 / 29 (0.00%) 0 | |
| Blood and lymphatic system disorders Thrombocytopenia subjects affected / exposed occurrences (all) | 0 / 26 (0.00%) 0 | 2 / 29 (6.90%) 2 | |
| Eye disorders Microvascular cranial nerve palsy subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 0 / 29 (0.00%) 0 | |
| Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 5 / 29 (17.24%) 5 | |
| Melaena | | | |

| | | | |
|--|---------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 26 (0.00%) 0 | 2 / 29 (6.90%) 2 | |
| Vomiting subjects affected / exposed occurrences (all) | 0 / 26 (0.00%) 0 | 1 / 29 (3.45%) 1 | |
| Oral candidiasis subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 0 / 29 (0.00%) 0 | |
| Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 0 / 29 (0.00%) 0 | |
| Renal and urinary disorders Acute kidney injury subjects affected / exposed occurrences (all) | 0 / 26 (0.00%) 0 | 2 / 29 (6.90%) 2 | |
| Anuria subjects affected / exposed occurrences (all) | 0 / 26 (0.00%) 0 | 1 / 29 (3.45%) 1 | |
| Acute on chronic liver failure subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 0 / 29 (0.00%) 0 | |
| Polyuria subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 0 / 29 (0.00%) 0 | |
| Infections and infestations Cholecystitis acute subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 0 / 29 (0.00%) 0 | |
| Sepsis subjects affected / exposed occurrences (all) | 2 / 26 (7.69%) 2 | 2 / 29 (6.90%) 2 | |
| Pneumonia subjects affected / exposed occurrences (all) | 2 / 26 (7.69%) 2 | 3 / 29 (10.34%) 3 | |
| Bacterial infection | | | |

| | | | |
|--|----------------------|---------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 26 (0.00%) 0 | 1 / 29 (3.45%) 1 | |
| Escherichia bacteraemia subjects affected / exposed occurrences (all) | 0 / 26 (0.00%) 0 | 1 / 29 (3.45%) 1 | |
| Enterococcus test positive subjects affected / exposed occurrences (all) | 0 / 26 (0.00%) 0 | 1 / 29 (3.45%) 1 | |
| Metabolism and nutrition disorders | | | |
| Fluid overload subjects affected / exposed occurrences (all) | 4 / 26 (15.38%) 4 | 0 / 29 (0.00%) 0 | |
| Hyperkalaemia subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 1 / 29 (3.45%) 1 | |
| Hypernatraemia subjects affected / exposed occurrences (all) | 2 / 26 (7.69%) 2 | 2 / 29 (6.90%) 2 | |
| Hypokalaemia subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 0 / 29 (0.00%) 0 | |
| Hyponatraemia subjects affected / exposed occurrences (all) | 1 / 26 (3.85%) 1 | 2 / 29 (6.90%) 2 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-----------------|---|
| 06 August 2019 | Additional exclusion criteria (ECMO, any other reason clinician deems unsuitable), clarification of endpoints and analysis, qualitative research manual, updated IMP label |
| 06 January 2020 | Addition of a meeting at the end of the study where participants will be invited to hear study results and asked for their feedback on study recruitment procedures and outcome measures, to inform the large trial |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

This is a feasibility/pilot study with the aim of determining the recruitment rate for a larger-scale trial and assessing trial procedures. It was not statistically powered to compare FFP and PCC in terms of effectiveness or safety.

Notes:

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/31815658>